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of Nebraska, Lincoln, Nebraska, United States of America, 3Center for Biotechnology, University of Nebraska, Lincoln, Nebraska, United States of America
Abstract
Trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) reduces triglyceride (TG) levels in adipocytes through multiple
pathways, with AMP-activated protein kinase (AMPK) generally facilitating, and peroxisome proliferator-activated receptor c
(PPARc) generally opposing these reductions. Sirtuin 1 (SIRT1), a histone/protein deacetylase that affects energy
homeostasis, often functions coordinately with AMPK, and is capable of binding to PPARc, thereby inhibiting its activity.
This study investigated the role of SIRT1 in the response of 3T3-L1 adipocytes to t10c12 CLA by testing the following
hypotheses: 1) SIRT1 is functionally required for robust TG reduction; and 2) SIRT1, AMPK, and PPARc cross regulate each
other. These experiments were performed by using activators, inhibitors, or siRNA knockdowns that affected these
pathways in t10c12 CLA-treated 3T3-L1 adipocytes. Inhibition of SIRT1 amounts or activity using siRNA, sirtinol,
nicotinamide, or etomoxir attenuated the amount of TG loss, while SIRT1 activator SRT1720 increased the TG loss. SRT1720
increased AMPK activity while sirtuin-specific inhibitors decreased AMPK activity. Reciprocally, an AMPK inhibitor reduced
SIRT1 activity. Treatment with t10c12 CLA increased PPARc phosphorylation in an AMPK-dependent manner and increased
the amount of PPARc bound to SIRT1. Reciprocally, a PPARc agonist attenuated AMPK and SIRT1 activity levels. These
results indicated SIRT1 increased TG loss and that cross regulation between SIRT1, AMPK, and PPARc occurred in 3T3-L1
adipocytes treated with t10c12 CLA.
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Introduction
Conjugated linoleic acid (CLA) reduces adiposity in human and
mouse adipocytes [1–4], and the trans-10, cis-12 CLA (t10c12 CLA)
isomer is capable of causing this response [5]. The rates of fatty
acid oxidation and lipolysis increased in t10c12 CLA-treated 3T3-
L1 adipocytes [6], while lipolysis increased and fatty acid
biosynthesis decreased in t10c12 CLA-treated human adipocytes
[7,8]. Molecular responses to t10c12 CLA include the activation of
AMP-activated protein kinase (AMPK) [9], integrated stress
response (ISR; [10,11]) or unfolded protein response (UPR;
[12]), mitogen-activated protein kinase (MAPK) cascades [7], and
attenuation of peroxisome proliferator-activated receptor c
(PPARc) protein levels [3]. Treatment with t10c12 CLA requires
nuclear factor kappa-B (NF-kB) for an inflammatory response
[3,4,10,13–15] that includes increased prostaglandin biosynthesis
in human adipocytes [11], in mouse white adipose tissue [16], and
3T3L1 adipocytes [17]. Despite this progress in understanding of
the pathways involved in the early perception of t10c12 CLA and
the complex regulation of the subsequent responses, much remains
unknown in this process.
AMPK is a central regulator of cellular energy levels that is
activated by increases in the cellular AMP/ATP ratio, various
cellular stresses [18,19], or treatment of adipocytes [9] or mice
[20] with t10c12 CLA or mixed isomers of CLA. AMPK activation
requires phosphorylation at Thr172 [21], and two of the target
proteins inhibited by phosphorylation by AMPK are acetyl-CoA
carboxylase (ACC), and fatty acid synthase, two key enzymes in
fatty acid biosynthesis. Through this and other mechanisms
[18,19], activated AMPK decreases lipogenesis, increases fatty
acid oxidation, and increases lipolysis in adipocytes in vitro and in
vivo [22]. Phenformin and metformin are structurally related
chemicals that can be used to activate AMPK [18,23]. Metformin
increases TG loss in t10c12 CLA treated adipocytes, while
compound C, a potent inhibitor of AMPK, attenuates TG loss
in this system [9].
PPARc is a ligand-activated nuclear receptor that regulates
lipogenesis and is a key regulatory point for controlling inflam-
mation in adipocytes [24]. PPARc forms a complex with nuclear
receptor corepressors 1 or 2 (NCoR1 or 2) in the absence of its
bound ligand [25]. PPARc transactivation activity is also reduced
by phosphorylation at Ser112 by extracellular signal-regulated
kinase (ERK), c-Jun N-terminal Kinase (JNK), or p38 MAPKs,
and a phosphorylation-dependent sumoylation at K107 [26]. In
addition, a non-genomic role for PPARc is emerging, as a number
of PPARc-dependent processes are too rapid to involve transcrip-
tional responses [27,28]. The critical role of PPARc in the
response to t10c12 CLA is demonstrated by the attenuated
responses that occur on addition of PPARc agonists [11,29,30].
Protein deacetylation is emerging as an important mechanism
for regulating energy balance [31,32]. Of the two major classes of
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histone/protein deacetylases in mammals, the NAD-dependent
class III sirtuins are structurally and enzymatically distinct from
those of the zinc-dependent class I/II deacetylases [33]. Within the
seven members of the sirtuin family, SIRT1 (sirtuin 1) is
particularly involved in regulating cell energy metabolism, cell
stress, and cell fate [34]. SIRT1 directly binds to NCoR1 and
directly or indirectly to PPARc to repress PPARc transactivation
activity, inhibit adipogenesis, and increase fat loss in adipocytes
[35]. SIRT1 deacetylates liver kinase B1 (LKB1), facilitating the
ability of LKB1 to phosphorylate AMPK, defining a SIRT1/
LKB1/AMPK signaling pathway that provides one of the
connections between SIRT1 and AMPK for regulating energy
metabolism [36,37]. SIRT1 also deacetylates NF-kB, thereby
modulating NF-kB transactivation activity [38,39]. Amongst the
chemicals that affect the activity of sirtuins, the activator SRT1720
preferentially activates SIRT1 [40], while sirtinol and nicotin-
amide are used as general sirtuin inhibitors that do not inhibit class
I/II deacetylases [41]. Nicotinamide is a direct product of the
sirtuin deacetylation reaction that inhibits sirtuin enzymes as a
non-competitive product inhibitor [42]. Etomoxir indirectly
inhibits sirtuin activity as it inhibits fatty acid transport into
mitochondria which prevents an increase in NAD+, an activator of
sirtuin activity [43].
In this study, we analyzed the functional role of SIRT1 in the
attenuation of TG levels in t10c12 CLA-treated 3T3-L1 adipo-
cytes. Our objectives were to test whether SIRT1 was functionally
required for robust triglyceride reduction, and whether SIRT1,
AMPK, and PPARc cross regulated each other in the response.
These experiments were performed with activators, inhibitors, or
siRNA that affected these pathways and analyzing their effects on
TG levels, fatty acid metabolism, and post-translational modifica-
tions or activity levels of SIRT1, AMPK, and PPARc.
Experimental Procedures
Reagents
Compound C was purchased from Calbiochem (San Diego,
CA). Bovine serum albumin (BSA, .99% fat free), dexametha-
sone, etomoxir, GW9662, insulin, isobutyl-1-methylxanthine,
metformin, nicotinamide, phenformin, and sirtinol were pur-
chased from Sigma (St. Louis, MO). Ciglitazone, pioglitazone,
rosiglitazone, and troglitazone were from Fisher (Pittsburgh, PA).
SRT1720 was from Cayman Chemical (Ann Arbor, MI). T10c12
CLA (90%, #UC-61-A) was from Nu-Chek Prep, Inc (Elysian,
MN). Antibodies to acetyl-NF-kB p65 (acetyl K310), p-PPARc
(phospho S112) and negative control siRNA were from Abcam
(Austin, TX). Protein A agarose beads, antibodies to b-actin,
NCoR1, NF-kB p65, PPARc, SIRT1, anti-goat or anti-rabbit
secondary antibodies coupled to horseradish peroxidase, and Sirt1
siRNA were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies to p-AMPK, AMPK, p-ACC, and ACC
were from Cell Signaling (Beverly, MA). T7 RNA polymerase
(P2077) and rNTPs (E6000) were purchased from Promega.
SiRNA to lamin A/C, non-target siRNA, and DharmaFECT Duo
transfection reagent (T-2010-02) were from Dharmacon (Thermo
Fisher Scientific, Boulder, CO).
3T3-L1 cell culture, differentiation, and chemicals
Low passage 3T3-L1 fibroblasts [44] were obtained (H. Green,
Harvard Medical School) and cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) containing
10% bovine calf serum (Fisher, Pittsburgh, PA) and differentiated
as described [9]. When present, chemicals were dissolved in
DMSO, with the exception that 2 mmol/L metformin and
0.1 mmol/L phenformin were dissolved in water, and were added
directly to the media at #0.2% of the final volume in the media.
An initial chemical concentration was determined from literature
values and a range of concentrations around this value were then
tested for their effects in vivo. From this data, the lowest effective
concentration was chosen and used at the following concentra-
tions: 5 mmol/L ciglitazone, 10 mmol/L compound C, 10 mmol/L
etomoxir, 10 mmol/L GW9662, 10 mmol/L nicotinamide,
5 mmol/L pioglitazone, 5 mmol/L rosiglitazone, 10 mmol/L
sirtinol, 8 mmol/L SRT1720, or 5 mmol/L troglitazone and were
added 1 h before adding fatty acids. Fatty acids, either linoleic acid
or trans-10, cis-12 CLA, were dissolved in 0.1 M KOH, diluted
into fatty acid free (.99%) bovine serum albumin (BSA) in
phosphate buffered saline at a 1:1 ratio (2 mmol/L BSA: 2 mmol/
L fatty acid), pH adjusted to 7.4, and added to the cultures
containing 4 to 6 d post-differentiated 3T3-L1 adipocytes [9]. We
used 50 mM t10c12 CLA if assaying chemicals that increased TG
loss, but otherwise used 100 mM t10c12 CLA.
Fatty acid biosynthesis, oxidation, and lipolysis assays
Fatty acid biosynthesis was measured in differentiated adipo-
cytes after 24 h of treatment by removing the treatment media and
incubating the adipocytes in Hanks’ Balanced Salt Solution
(HBSS; Invitrogen, Carlsbad, CA) containing 37 KBq [14C]-
acetate [specific activity 2.1 GBg/mmol, (PerkinElmer Radioiso-
topes, Waltham, MA)] for 30 min (incorporation was linear for
60 min). Cells were washed in PBS three times, pelleted, and then
resuspended in 100 ml PBS and 0.1% SDS. Lipids were extracted
in 1 ml of 2:1 chloroform:methanol [45] and measured by
scintillation counting. Cells briefly exposed to 37 KBq [14C]-
acetate, followed by immediate washing and extracted as above,
were used to determine background levels, which were subtracted
from sample values. Fatty acid oxidation was measured in
differentiated adipocytes in 3.5 cm culture plates 12 h after
starting treatments by adding 37 KBq [14C]-oleic acid [specific
activity 2.2 GBg/mmol, (PerkinElmer Radioisotopes, Waltham,
MA)] to the treatment media for 2 h and collecting [14C]-CO2 for
1 h in collection jars as reported [46]. For lipolysis assays, the TG
pool of differentiated adipocytes was labeled by adding 37 KBq
[14C]-acetate [specific activity 2.1 GBg/mmol, (PerkinElmer
Radioisotopes, Waltham, MA)] to the media for 4 h, after which
time the plates were washed four times with PBS, and specific
experimental media treatments were initiated. Media (0.1 ml) was
collected after 24 h, lipids extracted in 1 ml of 2:1 chloroform:-
methanol [45] and measured by scintillation counting. The use of
labeled [14C]-acetate and the 2:1 chloroform:methanol extraction
step considerably reduced non-specific background to 50 DPM, as
determined by using the above protocol on cells that had been
briefly exposed to 37 KBq [14C]-acetate in media.
siRNA transfections
For siRNA transfections, 3T3-L1 adipocytes, 4 to 5 d post
differentiation, were transfected by siQUEST transfection reagent
(Mirus, Madison, WI) or DharmaFECT Duo transfection reagent
(Dharmacon, Thermo Fisher Scientific, Boulder, CO) as described
[47]. For siQUEST transfections, concentrations of 2 ml of
siQUEST reagent per ml of media and 40 nmol/L of siRNA
were added 24 h before adding fatty acids. For DharmaFECT
Duo transfections, concentrations of 1.4 ml per cm2 of Dharma-
FECT Duo and 80 nmol/L of siRNA were added 24 h before
adding fatty acids.
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T7 transcription of oligonucleotide templates
In addition to commercially available siRNAs, we utilized
siRNAs derived from transcription of oligonucleotide templates
with T7 RNA Polymerase as described [48]. The siRNA sequences
used were: siRNA control sequence: 59-AAC AGU CGC GUU
UGC GAC UGG UCU CUU GAA CCA GUC GCA AAC GCG
ACU GCC UAU AGU GAG UCG UAU UA-39. LaminA/C
siRNA sequence: 59-AAG GAG GAG CUU GAC UUC CAG
UCU CUU GAA CUG GAA GUC AAG CUC CUC CCC UAU
AGU GAG UCG UAU UA-39. Sirt1 siRNA: 59-AAG GAG ACU
GCG AUG UUA UAA UCU CUU GAA UUA UAA CAU CGC
AGU CUC CCC UAU AGU GAG UCG UAU UA-39
Immunoblot analysis
Nuclear and cytosolic extracts were isolated using a nuclear
extract kit (Active Motif, Carlsbad, CA). Equal amounts of
proteins from whole cell, nuclear, or cytosolic extracts were
separated by SDS-PAGE, transferred to Immun-blot PVDF
membrane (Bio-Rad Laboratories, Hercules, CA), probed with
the indicated primary antibodies, and detected with secondary
antibodies. Enhanced chemiluminescence (Pierce, Rockford, IL)
was used for detection. Band intensities were determined from
digital images from exposures in the linear range using software
(Quantity One, Biorad, Hercules, CA). All western blot analyses
were repeated at least three times.
Immunoprecipitation
Immunoprecipitations were performed according to the proce-
dure described [35]. In brief, the collected 3T3-L1 adipocytes
were sonicated, lysates were centrifuged, and aliquots of the
supernatants were immunoprecipitated overnight with specific
antibody or control nonspecific IgG serum. Protein A agarose
beads were used to bind the specific or non-specific antibody
complexes, the protein A beads containing bound proteins were
washed five times, and the bound proteins were eluted in SDS
sample buffer for immunoblot analysis.
Quantification of TG content
Cell isolation and TG measurements were performed according
to the manufacturer’s instructions using TG reagent (T2449;
Sigma, St. Louis, MO) and free glycerol reagent (F6428; Sigma,
St. Louis, MO). TG data are expressed as nmol of TG per mg of
protein.
Measurement of MCP-1 and COX2 mRNA
Total RNA was extracted by TRIzol (Invitrogen) following the
manufacturer’s protocol. Total RNA (2 mg) was used for cDNA
synthesis. Real-time PCR was performed by a Bio-Rad iCycler
using iQ SYBR Green Supermix reagent (Bio-Rad, Hercules, CA)
using PCR primers for MCP-1 or glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) [9], and COX2 [9]. MCP-1 and COX2
mRNA levels were normalized to GAPDH, which showed no
significant variation in microarray analyses between linoleic acid
and t10c12 CLA treatments. Experiments were repeated three
times, and each sample was analyzed using one RNA control and
two replicates of each cDNA pool, and the relative amounts of
MCP-1, COX2 and GAPDH were calculated using the compar-
ative CT method [49], according to the manufacturer’s software
(Bio-Rad, Hercules, CA). Cycle numbers were used to calculate
gene expression levels in the log linear amplification range.
Statistical Analysis
One or two-way ANOVA was used to analyze the data. Post-
hoc pairwise comparisons were calculated using Tukey’s test and
were considered significant for p#0.05. All analyses were
performed using SAS software (SAS, Cary, NC).
Results
SIRT1 is required for reduced TG levels in t10c12 CLA-
treated adipocytes
We first determined whether increased SIRT1 activity would
affect TG levels in t10c12 CLA-treated differentiating adipocytes.
To specifically activate SIRT1, we used SRT1720, as this
chemical is known to preferentially activate SIRT1 at 8 mM
[40]. SRT1720, in combination with 50 mM t10c12 CLA,
significantly lowered TG to levels below those achieved by
50 mM t10c12 CLA alone (Fig. 1A). In contrast, addition of
100 mM t10c12 CLA in combination with a sirtuin inhibitor, either
sirtinol or nicotinamide, significantly increased TG levels, relative
to those from adipocytes treated with 100 mM t10c12 CLA alone
(Fig. 1. B). Etomoxir, which inhibits sirtuin activity indirectly by
reducing NAD+ levels via inhibition of mitochondrial fatty acid
transport and oxidation [43], was also tested. Treatment with
etomoxir and t10c12 CLA significantly increased TG levels
relative to TG levels with t10c12 CLA alone (Fig. 1C). These
data supported a hypothesis that one or more sirtuins participate
in the TG loss response caused by t10c12 CLA treatment, and that
SIRT1 involvement was likely due to the response to SRT1720, a
specific SIRT1 activator.
SiRNA was used to reduce SIRT1 expression to confirm the
functional involvement of SIRT1 in the response to t10c12 CLA.
First, to verify that SIRT1 protein levels were likely to respond to
siRNAi-mediated knockdown of its mRNA levels in t10c12 CLA-
treated adipocytes, the half-life of SIRT1 in cycloheximide treated
adipocytes was determined to be less than 6 h (Figure S1) and that
treatment with t10c12 CLA did not change SIRT1 protein levels
(Figure S2). We additionally verified that our siRNA transfection
method could deliver siRNA efficiently enough to knockdown
protein levels of Lamin A/C (Figure S3), a target known to be
susceptible to siRNA knockdown in adipocytes [47].
A siRNA targeted against SIRT1 mRNA significantly reduced
SIRT1 protein levels but did not affect b-actin levels, while a
control non-target siRNA did not change SIRT1 or b-actin
amounts (Fig. 1D). In the presence of t10c12 CLA, siRNA
knockdown of SIRT1 in adipocytes produced higher levels of TG
levels than those from adipocytes treated with a non-target siRNA
or reagent only controls (Fig. 1E). In the presence of LA, the
siRNA SIRT1 treated adipocytes had TG levels that were not
significantly different than those from adipocytes treated with the
control non-target siRNA or reagent (Fig. 1E). These results
indicate that siRNA knockdown of SIRT1 attenuated the TG loss
caused by t10c12 CLA. Taken together with the above inhibitor
studies, these results demonstrate that inhibition of SIRT1 activity
or protein levels significantly interfere with the TG loss caused by
t10c12 CLA. Further, the magnitude of the change in TG levels in
the inhibitor studies (Figures 1b and 1c) and when SIRT1 was
knocked down by siRNA (Figure 1e) indicates SIRT1 accounts for
most or all of the SIRT activity involved in lipid loss in t10c12
CLA treated adipocytes.
SIRT1 affects the rates of fatty acid metabolism and the
inflammatory response
The involvement of SIRT1 in t10c12 CLA-mediated changes in
the rates of fatty acid biosynthesis, oxidation, and lipolysis as well
Cross Regulation of Sirtuin 1
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as in the induction of two key inflammatory mRNAs was then
measured to gain insight into how SIRT1 affected these specific
pathways. Adipocytes treated with t10c12 CLA alone had a 77%
reduction in their rate of lipogenesis (Fig. 2A). The combination of
t10c12 CLA and sirtinol significantly changed this to a 47%
reduction in the rate of lipogenesis (Fig. 2A). This result indicated
SIRT1 activity was involved in inhibiting the rate of fatty acid
biosynthesis. Adipocytes treated with t10c12 CLA exported
significantly more radioactively-labeled lipids than LA treated
cells, but the amount of t10c12 CLA-mediated lipolysis was not
significantly affected by the sirtuin inhibitor sirtinol (Fig. 2B). The
rate of fatty acid oxidation was significantly increased in t10c12
CLA-treated adipocytes, and although fatty acid oxidation was less
when sirtinol was added, this difference was not significant
(Fig. 2C). In conclusion, it appears the major change in lipid
metabolism affected by SIRT1 is the rate of fatty acid biosynthesis.
The inflammatory MCP1 and COX2 mRNAs were highly
induced by t10c12 CLA treatment (Fig. 2D–E). The SIRT1
activator SRT1720, in combination with t10c12 CLA, modestly
attenuated the induction of MCP1 to 79% of t10c12 CLA levels,
and although COX2 mRNA levels were slightly lower, this latter
difference was not significant (Fig. 2D–E). In contrast, the SIRT1
inhibitors, sirtinol or nicotinamide, when used in combination with
t10c12 CLA, attenuated the induction of the mRNA of MCP1
relative to t10c12 CLA control levels (Fig. 2D). Similarly, sirtinol or
nicotinamide, when used in combination with t10c12 CLA,
attenuated the induction of the mRNA of COX2 relative to
10c12 CLA control levels (Fig. 2E). These results indicated SIRT1
partially increased the induction of the inflammatory MCP1 and
COX2 mRNAs, possibly through its inhibition of PPARc (see
below), which plays an anti-inflammatory role in adipocytes [24].
SIRT1 increases AMPK activity
We next determined whether SIRT1 affected AMPK regulation
during the response to t10c12 CLA. AMPK activity was measured
by the amount of phosphorylation at AMPK Thr172 (p-AMPK)
and by the amounts of phosphorylated ACC (p-ACC), one of
AMPK’s key substrates in vivo [50]. We previously demonstrated
the t10c12 CLA-stimulated increase in ACC phosphorylation was
less in compound C treated adipocytes, supporting the premise
that this phosphorylation was mediated by AMPK [9]. Although
p-AMPK levels were increased by 2 h of treatment with t10c12
CLA, the addition of SIRT1 activator SRT1720 or SIRT
inhibitors, had no significant effect on the amount of p-AMPK
or p-ACC produced after 2 h of treatment (Fig. 3A). However,
when used in combination with t10c12 CLA for 12 h, SIRT1
activator SRT1720 significantly increased p-AMPK or p-ACC
levels relative to the amounts present when treated by t10c12 CLA
alone (Fig. 3B). Conversely, when used in combination with t10c12
CLA for 12 h, SIRT1 inhibitors sirtinol or nicotinamide
significantly attenuated p-AMPK levels relative to the amounts
of these proteins in adipocytes treated with t10c12 CLA (Fig. 3B).
Similarly, when used in combination with t10c12 CLA, siRNA
targeting of SIRT1 significantly reduced p-AMPK and p-ACC
levels relative to the control treatment (Fig. 3C). Collectively, these
results indicated SIRT1 increased AMPK activity levels after 12 h,
but not 2 h, of exposure to t10c12 CLA.
A PPARc agonist or antagonist affects the TG loss
response to t10c12 CLA
The involvement of PPARc in the TG loss response to t10c12
CLA was then tested through addition of a PPARc antagonist or
agonist. The PPARc antagonist GW9662 significantly reduced
TG levels when used in combination with 50 mM t10c12 CLA
relative to TG levels in the t10c12 CLA treatment (Fig. 4A). Prior
to examining the effects of a PPARc agonist on the response to
t10c12 CLA, we first determined that troglitazone was the most
potent PPARc agonist amongst a set of four thiazolidinedione
agonists, as measured by their ability to increase the amount of TG
Figure 1. SIRT activity affects TG levels in t10c12 CLA treated 3T3-L1 adipocytes. a–c Triglyceride (TG) levels were measured in
differentiating adipocytes after incubation with LA (L) or t10c12 CLA (C), with or without the SIRT1 activator SRT1720 (SRT), or the sirtuin inhibitors
sirtinol (SOL), nicotinamide (NAM), or etomoxir (ETO) for 24 h. d Immunoblot analysis of whole cell extracts for the amount of SIRT1 and b-actin
proteins after exposure to 80 nmol/L of control siRNA (siCON), or siRNA against SIRT1 (siSirt1), or transfection reagent only. Duplicate loadings of each
sample were analyzed and the lanes marked by 1/3 have one third of the indicated samples loaded. e Triglyceride (TG) amounts after treatments as in
d. Each bar in panels a–c and e represents the mean + SEM (n= 3), and is representative of three independent experiments. Means not sharing a
common letter differ, Pƒ0.05. Panel d is a representative blot of three independent experiments.
doi:10.1371/journal.pone.0048874.g001
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produced in differentiating adipocytes (Fig. 4B). Troglitazone
significantly attenuated t10c12 CLA’s ability to reduce TG levels,
as the combined treatment was not significantly different from the
LA control (Fig. 4C). These results indicated that, in adipocytes
treated with t10c12 CLA, a PPARc antagonist facilitated TG loss
while a PPARc agonist interfered with TG loss.
Cross regulation of PPARc and AMPK in adipocytes
treated with t10c12 CLA
The cross regulation between PPARc and AMPK was next
determined. When used in combination with t10c12 CLA for 12 h,
PPARc antagonist GW9662 significantly increased AMPK and ACC
phosphorylation levels (Fig. 4D). Conversely, when used in combina-
tion with t10c12 CLA for 12 h, troglitazone significantly reduced
AMPK and ACC phosphorylation levels (Fig. 4D). However, when
used in combination with t10c12 CLA for only 2 h there was no
significant effect of these chemicals on AMPK or ACC phosphory-
lation levels (Fig. 4D). Therefore, although AMPK activation occurred
at 2 h, cross regulation by PPARc was not apparent at 2 h.
Phosphorylation of PPARc increased by 140% at 12 h, but not by
2 h, after t10c12 CLA treatment (Fig. 4E–F). When compound C was
used in combination with t10c12 CLA, the amount of phosphorylated
PPARcwas reduced relative to the levels when treated by t10c12 CLA.
This suggests AMPK activity was directly or indirectly involved in the
phosphorylation of PPARc (Fig. 4F). These results indicated AMPK
and PPARc cross regulated each other in the response to t10c12 CLA.
Cross regulation of PPARc and AMPK also occurs in the
absence of t10c12 CLA
We next determined whether this cross regulation between
AMPK and PPARc was a general aspect of these proteins by
testing whether this occurred in the absence of t10c12 CLA. This
was done by using two other chemicals to activate AMPK, alone
or in combination with a PPARc agonist or antagonist.
Phenformin, a strong AMPK activator, significantly reduced TG
levels to 60% of those present in the untreated control adipocytes
(Fig. 5A). When phenformin was used in combination with
troglitazone, significantly more TG was present than in adipocytes
treated with phenformin alone (Fig. 5A). Metformin, a weaker
AMPK activator, only slightly reduced TG levels (Fig. 5B). The
TG level was further reduced when metformin was used in
combination with the PPARc antagonist GW9662 (Fig. 5B). These
results indicated that the antagonistic cross regulation between
AMPK and PPARc that was observed in the response to t10c12
CLA also occurred in phenformin or metformin treated adipocytes
in the absence of t10c12 CLA.
NF-kB is deacetylated by one or more sirtuins in t10c12
CLA treated adipocytes
The regulation of SIRT1 activity by AMPK and PPARc was
then assessed. A known deacetylation target of SIRT1 is Lys310 of
the p65 subunit of NF-kB [38]. Therefore, we determined whether
the p65 subunit of NF-kB changed its acetylation levels in response
to t10c12 CLA. The acetylation level of the p65 subunit of NF-kB
was not significantly changed by treatment with t10c12 CLA for
2 h (Fig. 6A). In contrast, the amount of acetylated p65 subunit of
NF-kB was significantly less in adipocytes treated with t10c12 CLA
for 12 h (Fig. 6B). When t10c12 CLA was used in combination
with sirtinol or nicotinamide inhibitors of sirtuin activity, the
amount of the acetylated p65 subunit of NF-kB was significantly
higher relative to t10c12 CLA alone (Fig. 6 B). These drug
inhibition results supported the premise that one or more members
of the sirtuin family of protein deacetylases were involved in the
Figure 2. SIRT1 affects fatty acid metabolism and inflammatory mRNA levels. a–c The effects of 100 mmol/L of t10c12 CLA, with or without
the sirtuin inhibitor sirtinol (SOL), on the rates of fatty acid metabolism were measured by radioactive tracers (disintegrations per minute: dpm) as
follows: a fatty acid biosynthesis by incorporation of [1-14C]-acetate; b lipolysis by the release of lipids previously labeled with [1-14C]-acetate; c fatty
acid oxidation by the release of [14C]-CO2 from lipids previously labeled with [1-
14C]-oleate. d–e The effects of the SIRT1 activator SRT1720 (SRT), or
the sirtuin inhibitors sirtinol (SOL) or nicotinamide (NAM) on RNA levels in LA or t10c12 CLA treated adipocytes were analyzed for MCP-1 and COX2
relative to GAPDH by reverse transcription and quantitative PCR. The relative amounts of MCP-1 and COX2 mRNA are shown as bar graphs. Each bar
in panels a–e represents the mean + SEM (n= 3 for a–b or n = 2 for c–e), and is representative of three independent experiments. Means not sharing
a common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g002
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deacetylation of the p65 subunit of NF-kB. Of the seven sirtuin
family members, only SIRT1 and SIRT6 have a nuclear
localization [51] that overlaps with the subcellular localization of
acetylated NF-kB. Additionally, of the seven sirtuins, only SIRT1
is known to deacetylate the p65 subunit of NF-kB [38]. Therefore,
these results established that one or more members of the sirtuins,
presumably at least SIRT1, were responsible for the deacetylation
of the p65 subunit of NF-kB, and verified that sirtuin deacetylase
activity increased in t10c12 CLA treated adipocytes.
AMPK and PPARc affect SIRT1 activity
The involvement of AMPK in regulating SIRT1 activity was
then measured using compound C, an inhibitor of AMPK. The
amount of the acetylated p65 subunit of NF-kB significantly
increased in a treatment using t10c12 CLA in combination with
compound C, relative to the acetylation level produced by t10c12
CLA (Fig. 6C). This result indicated AMPK was directly or
indirectly involved in regulating the SIRT1 deacetylation response
to t10c12 CLA. The PPARc agonist troglitazone was used to
determine whether PPARc affected the levels of acetylation of the
p65 subunit of NF-kB. When used in combination with t10c12
CLA for 12 h, troglitazone-treated adipocytes significantly in-
creased the amount of acetylated p65 subunit of NF-kB relative to
the t10c12 CLA treatment, suggesting activated PPARc interferes
with SIRT1 deacetylation activity (Fig. 6D). Conversely, adipo-
cytes treated with t10c12 CLA and the PPARc antagonist
GW9662 significantly reduced the amounts of acetylated p65
subunit of NF-kB relative to the t10c12 CLA treatment, suggesting
inhibition of PPARc increases SIRT1 deacetylation activity
(Fig. 6D). Collectively, these results indicated that AMPK
positively regulated, and PPARc negatively regulated, SIRT1
activity in vivo, as measured by the deacetylation of the p65 subunit
of NF-kB.
SIRT1 increases its binding to PPARc and NCoR1 in
t10c12 CLA treated adipocytes
A possible mechanism for cross regulation of SIRT1 and
PPARc is through participation within a common protein
complex [35]. Using co-immunoprecipitation with a SIRT1
antibody, we observed that t10c12 CLA treatment resulted in a
significant increase in the amount of a SIRT1/PPARc protein
complex relative to the amount of this complex in the LA control,
despite an overall reduction in PPARc protein levels in t10c12
CLA treated cells (Fig. 7). Again using the same co-immunopre-
cipitation method, we observed that the amount of a protein
complex containing SIRT1 and NCoR1 also significantly
increased in the presence of t10c12 CLA (Fig. 7). These results
demonstrated that there was increased binding of SIRT1 to
PPARc and NCoR1 in t10c12 CLA treated adipocytes.
Discussion
Here we demonstrated that SIRT1 activity was functionally
involved in the TG loss response that occurred in t10c12 CLA-
treated 3T3-L1 adipocytes. Our chemical inhibitor and activator
studies indicated SIRT1 facilitated TG loss, as did AMPK, while
PPARc stimulated TG synthesis (summarized in Figure 8). Our
assays of protein activities, modifications, and interactions
supported this functional data and provided molecular evidence
of cross regulation between SIRT1, AMPK and PPARc in the
response to t10c12 CLA. As discussed below, each of these proteins
directly or indirectly affected the activity of the others.
In order to evaluate the effects of SIRT1 on specific pathways in
lipid metabolism, we first established the effects of t10c12 CLA on
Figure 3. SIRT1 affects ACC and AMPK phosphorylation levels
after t10c12 CLA treatment. Differentiated 3T3-L1 adipocytes were
incubated with 100 mmol/L LA (L) or t10c12 CLA (C): a with or without
SIRT1 activator SRT1720 (SRT), or sirtuin inhibitors sirtinol (SOL) or
nicotinamide (NAM) for 2 or b 12 h; or c with 40 nmol/L of SIRT1 siRNA
(siSIRT1) or control siRNA (siCON). Representative western blots indicate
the proteins detected in cytosolic extracts with antibodies to p-ACC (p-
Ser79), or total ACC, p-AMPK (p-Thr172), or total AMPK. Each bar in
panels a–c represents the mean + SEM (n= 3) of the ratio of the
phosphorylated to total form of each protein (phospho/total) for three
independent experiments. Means for p-AMPK/AMPK (a–e) or p-ACC/
ACC (u–x) not sharing a common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g003
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lipid metabolism in our 3T3-L1 adipocyte system. The decrease in
TG levels in t10c12 CLA-treated adipocytes was caused by a
combination of reduced fatty acid biosynthesis, increased lipolysis,
and increased fatty acid oxidation. Our finding that t10c12 CLA-
treated adipocytes have increased p-AMPK levels and increased
lipolysis and fatty acid oxidation is consistent with a report that
activated AMPK increases lipolysis and fatty acid oxidation [22].
Our results were also consistent with the increased lipolysis and
fatty acid oxidation, but not the increased fatty acid biosynthesis,
reported in t10c12 CLA-treated 3T3-L1 adipocytes [6]. The latter
difference may reflect differences in the specific cell cultures. The
reduction in the rate of fatty acid synthesis was consistent with the
reduced transcript levels of lipid biosynthetic enzymes such as
ACC1, ACC2, and fatty acid synthase in mice and 3T3-L1
adipocytes [10,15], possibly mediated by AMPK’s ability to
phosphorylate and inhibit SREBP1, a key regulatory factor of
these genes [52]. Further, the reduction in the rate of fatty acid
synthesis was consistent with increased phosphorylation of ACC,
which inhibits ACC (both ACC-1 and ACC-2 isoforms) and
thereby inhibits production of malonyl-CoA. Reduced concentra-
Figure 4. PPARc antagonists and agonists affect TG levels and modulate p-AMPK activity levels in t10c12 CLA treated 3T3-L1
adipocytes. a Differentiated adipocytes were incubated with 50 mmol/L LA (L) or t10c12 CLA (C) with or without PPARc antagonist GW9662 (9662)
for 24 h and TG levels were measured. b Differentiating adipocytes were treated with either control media (0), troglitazone (Tro), ciglitazone (C),
rosiglitazone (R), or pioglitazone (P) to determine which PPARc agonist was most effective for increasing TG levels. c Differentiated 3T3-L1 adipocytes
were incubated with 100 mmol/L LA or t10c12 CLA, with or without PPARc agonist troglitazone (Tro), and TG levels were measured after 24 h. d
Adipocytes were treated as in a or c for 2 or 12 h using 100 mmol/L LA or t10c12 CLA, and representative western blots of cytosolic extracts indicate
the proteins detected with antibodies to p-ACC (p-Ser79), total ACC, p-AMPK (p-Thr172), or total AMPK. The ratio of the phosphorylated to total form
of each protein (phospho/total) is shown in the bar graphs. e–f The amount of phosphorylated or total PPARc in nuclear extracts was measured after
2 or 12 h of treatment with 100 mmol/L LA or t10c12 CLA, and with or without compound C (Comp. C) at 12 h. The ratio of the amount of
phosphorylated to total PPARc is shown in the bar graphs. Each bar in panels a–f represents the mean + SEM (n= 3), and is representative of three
independent experiments (a–c) or is the mean of three independent experiments (d–f). Means within each data type (a–e or u–x) not sharing a
common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g004
Cross Regulation of Sirtuin 1
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e48874
tions of malonyl-CoA should reduce the rate of fatty acid
biosynthesis and increase the rate of fatty acid oxidation, as
attenuated levels of malonyl-CoA no longer inhibit carnitine
palmitoyltransferase-mediated transport of fatty acids into mito-
chondria for b-oxidation [18,19,50]. Fatty acid synthesis was also
Figure 5. PPARc agonists or antagonists affect the TG loss
caused by AMPK activators without t10c12 CLA being present.
a Differentiated 3T3-L1 adipocytes were incubated with or without
0.1 mmol/L phenformin (Phen), with or without PPARc agonist
troglitazone (Tro), and TG levels were measured after 24 h. b TG levels
were measured in differentiated 3T3-L1 adipocytes in media lacking or
containing 2 mmol/L metformin (Met), with or without PPARc
antagonist GW9662 (9662) for 24 h. Each bar represents the mean +
SEM (n= 3), and is representative of three independent experiments.
Means not sharing a common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g005
Figure 6. SIRT1, AMPK and PPARc affect the t10c12 CLA-dependent decrease in the amount of acetylated NF-kB. The amount of
acetylation on the p65 subunit of NF-kB or the total amount of p65 in nuclear extracts was detected by immunoblot analysis with antibodies specific
for acetylated p65 or total p65. The ratio of the acetylated to total p65 is shown in the bar graphs (Acetyl-p65/p65). a–c Differentiated 3T3-L1
adipocytes were incubated with 100 mmol/L LA (L) or t10c12 CLA (C) a for 2 h, or b for 12 h, with or without sirtuin inhibitors sirtinol (SOL) or
nicotinamide (NAM), or c with or without AMPK inhibitor compound C (Comp.C). d The effects of PPARc agonist troglitazone (Tro) or PPARc
antagonist GW9662 (9662), in combination with LA or t10c12 CLA, on the acetylation of the p65 subunit of NF-kB was measured. Each bar in panels
a–d represents the mean + SEM (n= 3) of three independent experiments. Means not sharing a common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g006
Figure 7. Treatment with t10c12 CLA increases the interaction
of SIRT1 with PPARc or NCoR1. Differentiated 3T3-L1 adipocytes
were incubated with 100 mmol/L LA (L) or t10c12 CLA (C) for 12 h, and a
portion of the nuclear extracts were immunoprecipitated with antibody
to SIRT1 (IP: SIRT1). Representative immunoblots (IB) indicate the
proteins detected from the nuclear extracts (5% input) or when the
immunoprecipitated proteins were probed with antibodies to SIRT1,
PPARc, or NCoR1. Each bar represents the mean + SEM (n= 3) of three
independent experiments. Means within each data type not sharing a
common letter differ, Pƒ0.05.
doi:10.1371/journal.pone.0048874.g007
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likely reduced by AMPK’s ability to phosphorylate and inhibit
fatty acid synthase [18,19]. Our studies indicated that SIRT1
primarily affected the rate of fatty acid biosynthesis as inhibition of
SIRT1 did not significantly affect the rate of lipolysis or fatty acid
oxidation in the response to t10c12 CLA. Whether SIRT1
regulates fatty acid biosynthesis primarily via differential modu-
lation of the activities of AMPK and PPARc or additionally
through direct deacetylation of metabolic enzymes [53] requires
additional research.
Our results strongly support an increase in SIRT1 deacetylase
activity occurs in vivo in t10c12 CLA treated adipocytes. We used
the acetylation levels of Lys310 of the p65 subunit of NF-kB as an
indicator of SIRT1 deacetylase activity in vivo. NF-kB/p65 had
reduced amounts of acetylation at Lys310 in t10c12 CLA-treated
adipocytes, indicating increased deacetylase activity was occurring.
However, in principle Lys310 of p65/NF-kB can be deacetylated
by both class I/II or sirtuin deacetylases [38]. Results with the
sirtuin-specific inhibitors indicated the majority of NF-kB/p65
deacetylation was accomplished by the sirtuin class of deacetylases.
Of the seven sirtuin family members, only SIRT1 and SIRT6 have
the nuclear localization [51] needed to deacetylate nuclear-
localized NF-kB. Of these two candidates, SIRT1 is likely to be
involved as SIRT1 physically binds to the p65 subunit of NF-kB
and deacetylates it at Lys310 in human lung cells [38]. Further,
our siRNA knockdown of SIRT1 indicates it is the major
contributor to SIRT function in the t10c12 CLA response
(Figure 1E). Therefore, our results strongly support an increase
in the deacetylase activity of SIRT1 in t10c12 CLA-treated
adipocytes, without ruling out minor contributions from other
sirtuins.
The functional consequences of alterations in SIRT1, AMPK,
and PPARc activities suggested there was cross-regulation
between these proteins (summarized in Figure 8). Therefore,
evidence for changes in protein modifications and/or activity was
investigated. In the case of SIRT1 affecting AMPK, an activator of
SIRT1 increased AMPK activity, while inhibitors of SIRT1
reduced AMPK activity in t10c12 CLA-treated adipocytes. A
possible pathway connecting SIRT1 to AMPK is a SIRT1/
LKB1/AMPK axis by which SIRT1 can affect AMPK activity via
deacetylation of protein kinase LKB1, which increases LKB1’s
ability to activate AMPK by phosphorylation [36,37]. In the case
of SIRT1 affecting PPARc, we found treatment with t10c12 CLA
caused more SIRT1 to bind to PPARc and NCoR1. This is likely
to inhibit PPARc activity as the increased binding of SIRT1 to
PPARc and NCoR1 that occurred during fasting reduced PPARc
transcriptional activity [35]. Reduced PPARc activity is consistent
with the reduced transcription of lipogenic genes observed in
t10c12 CLA treated adipocytes [10,13,15]. These results support a
conclusion that SIRT1 stimulated AMPK activity and attenuated
PPARc activity in t10c12 CLA treated adipocytes.
In the case of AMPK affecting SIRT1, inhibition of AMPK
with compound C reduced SIRT1 activity as measured by the
deacetylation of p65/NF-kB. The mechanism is unclear but could
include AMPK-mediated changes in fatty acid oxidation which
affect the NAD+/NADH ratio that affects SIRT1 activity [43]. In
the case of AMPK affecting PPARc, AMPK was directly or
indirectly responsible for the increased phosphorylated at Ser112
of PPARc in t10c12 CLA treated adipocytes [29], as this effect was
attenuated by the AMPK inhibitor compound C. Phosphorylation
of PPARc at Ser112 facilitates its SUMOylation at K107, and
thereby decreasing its transactivation activity [26]. These results
support a conclusion that AMPK stimulated SIRT1 activity and
attenuated PPARc activity in t10c12 CLA treated adipocytes.
In the case of PPARc affecting AMPK and SIRT1, troglita-
zone, a PPARc agonist, reduced the activities of AMPK and
SIRT1. Conversely, GW9662, an antagonist of PPARc, increased
the activities of AMPK and SIRT1. These results demonstrate that
PPARc has a repressive effect on the activities of these proteins,
which is consistent with the opposing roles of PPARc’s in
stimulating lipid biosynthesis and the catabolic energy-generating
roles of AMPK and SIRT1 [30,54]. The mechanisms of how
PPARc affects AMPK and SIRT1 are unclear, despite the
physical interaction between SIRT1 and PPARc [35,55].
Although the mechanisms are unclear, PPARc affected the
activity levels of SIRT1 and AMPK without changing the total
amounts of these proteins in the response to t10c12 CLA. This
suggests that PPARc achieved these effects via a non-transcrip-
tional mechanism. As such, our results support an emerging role
for PPARc in regulating non-genomic processes [27,28].
We also used AMPK activators in addition to t10c12 CLA to
manipulate AMPK activity and explore whether cross regulation
of AMPK and PPARc occurred in the absence of t10c12 CLA
(summarized in Figure 8). Phenformin, a potent AMPK activator,
caused a TG loss similar to that caused by t10c12 CLA treatment.
Troglitazone, the most potent PPARc agonist in our 3T3-L1
adipocyte system, attenuated the TG loss caused by phenformin.
Conversely, GW9662, a PPARc antagonist, increased the amount
of TG loss when used with metformin, a moderate AMPK
activator. This latter finding supports a hypothesis that both
AMPK activation [9] and reduced PPARc activity [3] are
important for reducing TG levels. Taken together, these results
support a hypothesis that cross regulation between AMPK and
PPARc also occurs in the absence of t10c12 CLA, and is therefore
likely to generally occur between these proteins in adipocytes.
Both AMPK and SIRT1 play major roles in regulating cellular
energy homeostasis and in response to caloric restriction
[54,56,57]. The involvement of AMPK and SIRT1 in the
response to t10c12 CLA is consistent with an overall similarity to
cellular energy restriction. This is supported by the strong
similarity of the whole genome transcriptional response of
adipocytes treated with t10c12 CLA to the response caused by
metformin [9], which affects the cellular AMP/ATP ratio [58,59].
Similarly, phenformin, which also affects the cellular AMP/ATP
ratio, caused TG losses similar to those caused by t10c12 CLA and
caused a whole genome transcriptional response similar to that of
Figure 8. Summary diagram for proposed effects of AMPK,
SIRT1, PPARc, and their activators or inhibitors in 3T3-L1
adipocytes. AMPK and SIRT1 impair lipid synthesis and PPARc activity
(red lines with stop bars), and stimulate each other (blue arrows). PPARc
impairs AMPK and SIRT1 activity and stimulates lipid synthesis. The
activating (blue arrows) or inhibiting (red line with stop bar) effects of
the different chemical activators and inhibitors are also shown.
doi:10.1371/journal.pone.0048874.g008
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t10c12 CLA-treated adipocytes [17]. Our results indicated SIRT1
activation and cross regulation of AMPK occurred at 12 h but not
as early as 2 h, while AMPK was activated at 2 h or earlier [9].
This is consistent with the suggestion that AMPK activation is a
critical early event [9]. The signaling pathways used by t10c12
CLA to activate AMPK remain unknown.
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